Comparison of the neurocognitive outcomes in term infants treated with levetiracetam and phenobarbital monotherapy for neonatal clinical seizures

Basit Öğe Kaydı
dc.contributor.authorArican, Pinar
dc.contributor.authorDundar, Nihal Olgac
dc.contributor.authorAtasever, Neslihan Mete
dc.contributor.authorInal, Mine Akkaya
dc.contributor.authorGencpinar, Pinar
dc.contributor.authorCavusoglu, Dilek
dc.contributor.authorTekgul, Hasan
dc.date.accessioned2020-12-01T11:58:43Z
dc.date.available2020-12-01T11:58:43Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose: This study aims to compare the neurocognitive outcome in term infants who were treated using phenobarbital (PB) and levetiracetam (LEV) monotherapy for neonatal clinical seizures. Methods: Term infants who were treated using PB or LEV monotherapy as the first-line anti-epileptic treatment for neonatal clinical seizures and followed-up in a pediatric neurology outpatient clinic were enrolled in this study. Neurodevelopmental outcome assessments were carried out using the Bayley Scales of Infant Development, third edition (BSID-III), including cognitive, receptive language, expressive language, fine motor and gross motor subscales. Results: the study group consisted of 62 infants who received monotherapy with PB monotherapy (n = 22) and LEV (n = 40). the mean duration of monotherapy treatment was 8 +/- 6 months. There was no statistically significant difference between PB and LEV monotherapy groups concerning each outcome parameter on the BSID-III. There was also no statistically significant difference between PB and LEV monotherapy subgroups excluding the infants with neurodevelopmental impairment with a BSID-III scale score < 7 or a composite score < 85. Conclusion: Our findings suggest that both LEV and PB therapy can be equally safe as monotherapy for neonatal clinical seizures for the neurodevelopmental outcome assessment with BSID-III.en_US
dc.identifier.doi10.1016/j.seizure.2020.06.006en_US
dc.identifier.endpage74en_US
dc.identifier.issn1059-1311
dc.identifier.issn1532-2688
dc.identifier.pmid32540641en_US
dc.identifier.scopus2-s2.0-85086820867en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage71en_US
dc.identifier.urihttps://doi.org/10.1016/j.seizure.2020.06.006
dc.identifier.urihttps://hdl.handle.net/11454/62092
dc.identifier.volume80en_US
dc.identifier.wosWOS:000565178800018en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherW B Saunders Co Ltden_US
dc.relation.ispartofSeizure-European Journal of Epilepsyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInfanten_US
dc.subjectMonotherapyen_US
dc.subjectNeonatalen_US
dc.subjectNeurodevelopmenten_US
dc.subjectSeizureen_US
dc.titleComparison of the neurocognitive outcomes in term infants treated with levetiracetam and phenobarbital monotherapy for neonatal clinical seizuresen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu